Title:

Contribution of genetic and environmental factors to the onset of preclinical Alzheimer's disease - a monozygotic twin study

Running head:

Preclinical Alzheimer's disease in monozygotic twins

Authors:

Elles Konijnenberg^{1†}, Jori Tomassen^{1†}, Anouk den Braber^{1,2}, Mara ten Kate¹, Maqsood M. Yaqub³, Sandra D. Mulder⁴, Michel G. Nivard², Hugo Vanderstichele⁵, Adriaan A. Lammertsma³, Charlotte E. Teunissen⁴, Bart N.M. van Berckel³, Dorret I. Boomsma², Philip Scheltens¹, Betty M. Tijms¹, Pieter Jelle Visser^{1,6,7}.

¹ Amsterdam UMC, VU University, Department of Neurology & Alzheimer Center, Neuroscience Amsterdam, Amsterdam, The Netherlands.

² VU University Amsterdam, Department of Biological Psychology, Neuroscience Amsterdam, Amsterdam, The Netherlands.

³ Amsterdam UMC, VU University, Department of Radiology & Nuclear Medicine, Neuroscience Amsterdam, Amsterdam, The Netherlands.

⁴ Amsterdam UMC, VU University, Neurochemistry Laboratory Department of Clinical Chemistry, Amsterdam Neuroscience, Amsterdam, The Netherlands.

⁵ ADx NeuroSciences, working on behalf of Biomarkable bvba, Gent, Belgium.

⁶ Alzheimer Center Limburg, School for Mental Health and Neuroscience, Maastricht University, Maastricht, the Netherlands.

⁷ Department of Neurobiology, Care Sciences and Society, Division of Neurogeriatrics, Karolinska Institutet, Stockholm Sweden.

† Authors contributed equally.

Corresponding author:

Jori Tomassen

Amsterdam UMC, VU University, Department of Neurology & Alzheimer Center,
PO Box 7057, 1007 MB Amsterdam, the Netherlands.

Phone: +31 20 444 8527; Fax: +31 20 444 8529

e-mail address: j.tomassen@amsterdamumc.nl

Keywords: Preclinical Alzheimer's disease, monozygotic twins, amyloid production and aggregation markers, tau

Preclinical Alzheimer's disease in monozygotic twins

Abstract (250 words)

Objective: To study the genetic contribution to the start of Alzheimer's disease as signified by abnormalities in amyloid and tau biomarkers in cognitively intact older identical twins.

Methods: We studied in 96 monozygotic twin-pairs relationships between A β aggregation as measured by the ratio A β 1-42/1-40 in cerebrospinal fluid (CSF) and positron emission tomography (PET), and CSF markers for A β production (BACE1, A β 1-40 and 1-38) and tau. Associations amongst markers were tested with Generalized Estimating Equations including a random effect for twin status, adjusted for age, gender, and APOE ϵ 4 genotype. We used twin analyses to determine relative contributions of genetic and/or environmental factors to AD pathophysiological processes.

Results: Twenty-seven individuals (14%) had an abnormal amyloid-PET, and 14 twin-pairs (15%) showed discordant amyloid status. Within twin-pairs, A β production markers and total-tau (t-tau) levels strongly correlated (r range 0.76, 0.88; all $p < 0.0001$), and A β aggregation markers and 181-phosphorylated-tau (p-tau) levels correlated moderately strong (r range 0.49, 0.52; all $p < 0.0001$). Cross-twin cross-trait analysis showed that A β 1-38 in one twin correlated with A β 1-42/1-40 ratios, t-tau and p-tau levels in their co-twins (r range 0.18, 0.58; all $p < .07$). Within-pair differences in A β production markers related to differences in tau levels (r range 0.49, 0.61; all $p < 0.0001$). Twin discordance analyses suggest that A β production and tau levels show coordinated increases in very early AD.

Interpretation: Our results suggest a substantial genetic/shared environmental background contributes to both A β and tau increases, suggesting that modulation of environmental risk factors may aid in delaying the onset of AD pathophysiological processes.

1. Introduction

Aggregation of amyloid-beta 1-42 (A β 1-42) in the brain can start up to 20 years before the onset of dementia¹, followed by tau pathology and cognitive decline^{2,3}. The mechanisms leading to A β aggregation and tau pathology are not fully understood, while such knowledge is crucial for the development of primary and secondary prevention strategies. Therefore it is important to understand the contribution of genetic and environmental factors in the early development of the disease, when biomarkers for A β and tau are changing and cognition is still intact. Twin studies suggested that genetic factors may explain 80% of the variance in AD-type dementia^{4,5}, but it remains largely unknown whether this is also the case for AD biomarkers in elderly cognitively normal individuals^{6,7}.

In autosomal dominant variants of Alzheimer's disease (ADAD), A β aggregation is associated with increased A β production. In sporadic Alzheimer's disease (AD), however, impaired clearance is suggested to drive the disease^{8,9}. Nevertheless, iPSC models in sporadic AD suggest that increased A β production and tau secretion are also involved¹⁰. In people, higher cerebrospinal fluid (CSF) BACE1 levels, the rate-limiting enzyme in A β production, have been associated with higher CSF concentrations of A β peptides¹¹, and subsequent aggregation of A β 1-42 in individuals with initially normal A β CSF levels¹².

While it is generally assumed that tau follows A β pathology¹³, CSF levels of total-tau (t-tau) and 181-phosphorylated-tau (p-tau) are also increased early in the disease¹⁴. Possibly, such early increases in CSF tau and A β levels are driven by common upstream pathophysiological processes¹⁵, and in order to identify such upstream processes it is important to determine the relative contributions of genetic and environmental factors to early changes in these AD pathophysiological processes. A monozygotic twin design provides a unique approach to study the role of genetic and environmental factors in disease

Preclinical Alzheimer's disease in monozygotic twins

development. Since monozygotic twins are genetically identical, differences for a trait within twin-pairs result from differences in unique environmental exposure.

Our objective was to investigate associations between A β production, A β aggregation and CSF tau pathology in cognitively intact older monozygotic twins, to determine the role of genetic and environmental factors on these associations. We used twin discordance models to test the dynamic relationship between A β production, A β aggregation markers: because twin concordance for AD increases with age⁴, we hypothesized that if A β production precedes A β aggregation, then in twin-pairs discordant for A β aggregation, the discordant twin with normal A β levels would already show signs of increased A β production markers compared to twin-pairs with normal A β markers. Furthermore, if A β and tau pathology are driven by common upstream pathophysiological processes, then higher levels of A β markers in one twin should be related to higher levels of tau levels in the co-twin in cross-twin cross-trait (CTCT) analysis. If associations between tau and A β markers are driven by unique environmental factors, then twin differences in these markers should be correlated. Furthermore, we investigated whether these analyses depend on the modality used to determine A β abnormality (i.e., positron emission tomography (PET) or CSF).¹⁶

2. Methods

2.1. Participants

Monozygotic twins were invited from the Netherlands Twin Register (NTR)¹⁷ to participate in the PreclinAD study as part of the Innovative Medicine Initiative (IMI) European Information Framework for AD (EMIF-AD) project (<http://www.emif.eu/>)¹⁸. Inclusion criteria were age 60 years and older, a delayed recall score of > -1.5 SD of demographically adjusted normative data of the Consortium to Establish a Registry for Alzheimer's Disease (CERAD) 10 word list¹⁹, a Telephone Interview for Cognitive Status modified (TICS-m) score of 23 or higher²⁰, a 15-item

Preclinical Alzheimer's disease in monozygotic twins

Geriatric Depression Scale (GDS) score of <11 ²¹, and a Clinical Dementia Rating (CDR) scale of 0 with a score on the memory sub domain of 0²². Exclusion criteria were any physical, neurological or psychiatric condition that could lead to interference with normal cognition in aging. Monozygotic twins were asked to collect buccal cell samples for DNA extraction to confirm zygosity. For the present study we included all individuals who had an amyloid measurement available (n=197).

2.2. Ethical considerations

Informed consent was obtained from all participants. The study was approved by the Central Ethics Committee on Research Involving Human Subjects of the VU University Medical Centre, Amsterdam, an Institutional Review Board certified by the U.S. Office of Human Research Protections (IRB number IRB00002991 under Federal-wide Assurance-FWA00017598). The research was performed according to the principles of the Declaration of Helsinki and in accordance with the Medical Research Involving Human Subjects Act and codes on 'good use' of clinical data and biological samples as developed by the Dutch Federation of Medical Scientific Societies. The study was registered in the EU Clinical Trials Register (EudraCT) with number 2014-000219-15.

2.3. Cerebrospinal fluid analysis

To determine A β aggregation in CSF we used the A β 1-42/1-40 ratio with lower values indicating abnormality²³. As markers for A β production we used BACE1 concentrations in CSF, as well as concentrations of A β 1-40 (A β 40) and 1-38 (A β 38)²⁴. For tau pathology we used CSF t-tau and p-tau^{25,26}, which reflect different aspects of tau pathology^{25,27-29}, with especially higher values for p-tau being indicative for tau aggregation. CSF samples were collected in 126 (62%) participants through a lumbar puncture, performed between 10am and 2pm, after at least two hours of fasting. Maximal 20 ml CSF was collected in Sarstedt

polypropylene syringes using a Spinocan 25 Gauge needle in one of the intervertebral spaces between L3 and S1. Samples were centrifuged at 1300-2000 g at 4°C for 10 minutes and supernatants were then stored in aliquots at -80°C until analysis³⁰. A maximum of 2 hours was allowed between lumbar puncture and freezing. Levels of A β 1-38, 1-40, 1-42, BACE1, t-tau and p-tau were analyzed using commercial kits from Euroimmun AG (Lübeck, Germany) according to manufacturer instructions³¹. All samples were measured in kits from the same lot.

2.4. [¹⁸F]flutemetamol positron emission tomography

To determine A β aggregation on PET imaging we used parametric non-displaceable binding potential (BP_{ND}) of the [¹⁸F]flutemetamol tracer, with higher binding of A β radioligands indicating the presence of plaques³²⁻³⁴. 196 subjects (94 twin-pairs) had [¹⁸F]flutemetamol PET available. In general, PET scanning was performed on the same day as the lumbar puncture, except for 26 subjects, due to technical issues (range 2.2 months before to 6.7 months after lumbar puncture). PET scans were acquired using a Philips Ingenuity TF PET-MRI camera (Philips Healthcare, Cleveland, USA). All subjects were scanned under standard resting conditions (eyes closed in dimmed ambient light) from 0 to 30 minutes and from 90 to 110 minutes after intravenous injection of 185 MBq ($\pm 10\%$) [¹⁸F]flutemetamol³⁴. After data acquisition, the first emission scan was reconstructed into 18 frames of increasing length (6x5, 3x10, 4x60, 2x150, 2x300 and 1x600 s.) using the standard LOR-RAMLA reconstruction algorithm for the brain. Using the same reconstruction algorithm, the second scan was reconstructed into 4 frames of 5 minutes each. Subsequently, data from the two scans were combined into a single image data set after co-registration using Vinci Software 2.56 (Max Planck Institute for Neurological Research, Cologne, Germany). Parametric non-displaceable binding potential (BP_{ND}) images were generated from the entire image set using receptor parametric mapping^{35,36}. Cerebellar grey matter, defined on a T1-weighted structural MRI scan

Preclinical Alzheimer's disease in monozygotic twins

obtained immediately prior to the PET scan, was used for attenuation correction of the PET data and as reference tissue³⁷. T1-based VOIs using the Hammers atlas implemented in PVElab software were projected onto the [¹⁸F]flutemetamol parametric images to extract regional values³⁸. A global BP_{ND} was calculated based on the volume-weighted average of frontal (i.e. superior, middle, and inferior frontal gyrus), parietal (i.e., posterior cingulate, superior parietal gyrus, postcentral gyrus, and inferolateral remainder of parietal lobe), and temporal (i.e. parahippocampal gyrus, hippocampus, medial temporal lobe, superior, middle, and inferior temporal gyrus) cortical regions³⁹. We classified twins as amyloid positive (abnormal) or negative (normal) by visual read of the [¹⁸F]flutemetamol scans. Rating was performed on the parametric BP_{ND} images by three readers (nuclear physician or radiologist) all trained according to GEHC guidelines^{40,41}. For 15 cases not all readers agreed, here we used the consensus rating of 2 readers. In quantitative analyses we used the global BP_{ND}.

2.6. APOE genotyping

To assess APOE ε4 allele carriership, the major genetic risk factor for sporadic AD, all subjects were genotyped on the Affymetrix Axiom array and the Affymetrix 6 array⁴². These were first cross chip imputed following the protocols as described by Fedko and colleagues⁴³ and then imputed to HRC with the Michigan Imputation server⁴⁴. APOE genotype was assessed using imputed dosages of the SNP rs429358 (APOE ε4, imputation quality = 0.956) and rs7412 (APOE ε2, imputation quality = 0.729)⁴⁵.

2.7. Statistical analysis

We used Generalized Estimating Equations (GEE) to test amyloid-PET group differences for demographic variables, including random effect for twin status. We then assessed associations between Aβ and tau markers across the total group, using GEE including random effect for twin

Preclinical Alzheimer's disease in monozygotic twins

status. Analyses were performed unadjusted (model 1) and adjusted for age, gender, and APOE $\epsilon 4$ genotype (model 2) when applicable⁴⁶. Next we performed three types of twin analyses. Monozygotic twin-pair correlations (i.e. correlations for a trait between twin 1 and twin 2 across the group) for CSF (n=54 pairs) and PET amyloid (n=94 pairs) were assessed using Pearson's correlations, which provides a proxy of variance explained in a trait by the combination of shared genetic and shared environmental factors. The correlation coefficient-1 indicates the percentage of the trait explained by unique environmental factors. Partial correlations were also calculated adjusting for age, gender and APOE $\epsilon 4$ genotype. PET data and CSF tau data were log-transformed to improve normal distribution of the data. When two variables showed a significant association, we performed CTCT analysis to test whether levels of marker A in one twin could predict levels of marker B in the co-twin using OpenMx⁴⁷. We also performed a monozygotic within-pair difference analysis⁴⁸ when there was a significant association between variables. This analysis allows examining whether within-pair differences in marker A can be explained by within-pair differences in marker B. It provides insight into the contribution of unique environmental factors unique to a twin on the observed relation between traits⁴⁸. Statistical analyses were performed in SPSS version 23 for Windows and R version 3.3.1, <http://www.r-project.org/>.

3. Results

Sample description

Twenty-seven individuals (14%) had an abnormal visual read of the amyloid-PET scan. These subjects were older and had lower CSF A β 1-42/1-40 ratios and higher p-tau levels compared to individuals with a normal PET scan (Table 1).

Twin-pair correlations

Preclinical Alzheimer's disease in monozygotic twins

Monozygotic twin-pair correlations (i.e. correlation for a trait across paired twins) were strong for A β production markers (r ranging between 0.76 and 0.85) and t-tau ($r=0.70$), and moderately strong for A β aggregation markers (r range 0.50, 0.52) and p-tau ($r=0.49$) (Fig. 2, Table 3). None of the markers tested were correlated across unrelated individuals (r range 0.05, 0.3; all $p<0.99$), and effect sizes remained similar when correcting for age, gender and APOE $\epsilon 4$ (Table 3).

Association between A β and tau markers across the total group

Across all subjects, higher levels of CSF BACE1 and A $\beta 38$ were associated with lower CSF A β 1-42/1-40 ratios but not with amyloid-PET BP_{ND}, and with higher levels of CSF t-tau and p-tau. Furthermore, lower CSF A β 1-42/1-40 ratios and higher amyloid-PET BP_{ND} were associated with higher levels of t-tau and p-tau, with p-tau showing a higher association with amyloid-PET BP_{ND} than t-tau (0.47 vs 0.25), Table 2).

Discordant twin-pair analyses

Seventy-four pairs (79% of the 94 complete PET imaging pairs) had both a normal amyloid-PET visual read (i.e., concordant normal), 14 pairs (15%) were discordant, and 6 pairs (6%) were concordant abnormal (Fig. 1). The discordant twin with normal amyloid-PET visual reads had higher BP_{ND} values compared to concordant twins with both normal amyloid-PET visual reads ($p<0.05$, Fig. 1H), suggesting that A β aggregation has already started in discordant normal twins, although still visually normal. Both amyloid abnormal and amyloid normal twins from discordant twin-pairs had higher BACE1 concentrations compared to concordant normal amyloid-PET twins (Fig. 1D), suggesting that increased BACE1 activity may indicate a very early event in sporadic AD⁴⁹. The twin with normal amyloid from

Preclinical Alzheimer's disease in monozygotic twins

discordant pairs showed higher levels of t-tau and p-tau compared to concordant normal twin-pairs, which suggests that also tau levels are increased very early in the disease (Fig. 1I-J).

CTCT and twin difference analyses

CTCT analyses showed that higher BACE1 and A β 38 concentrations in one twin correlated with lower A β 1-42/1-40 ratios in the co-twin, and even stronger so with higher t-tau and p-tau levels (A β aggregation: $r=-0.18$ - -0.24 , $p=0.07$ - 0.007 ; t-tau: $r=0.56$ - 0.58 , $p<0.0001$; p-tau: $r=0.32$ - 0.54 , $p<0.0001$ - 0.002 , Table 4A). Within-pair differences in production markers were also related to within-pair differences in tau levels (t-tau: $r=0.52$ - 0.61 , $p<0.0001$; p-tau: $r=0.49$ - 0.54 , $p<0.0001$, Table 4B), but not to within-pair differences in A β aggregation markers. CTCT analyses and within-pair differences further showed that aggregation markers (i.e. lower A β 1-42/1-40 ratios and higher amyloid PET-BP_{ND} values) in one twin predicted higher t-tau and p-tau levels in their co-twin (Table 4).

Comparison of CSF and PET A β markers, and t-tau with p-tau markers

We further studied the relationship between PET and CSF markers for A β aggregation, and observed moderately strong correlations between PET-BP_{ND} and the CSF A β 1-42/1-40 ratio across the total sample ($\beta=-0.57$ (SE=0.09), $p<0.0001$; Table 2), with CTCT ($r=-0.33$ (SE=0.09), $p=0.0005$; Table 4A) and within-pair difference analyses ($\beta=-0.58$ (SE=0.14), $p<0.0001$; Table 4B, Fig. 3). For t-tau and p-tau we observed high total sample correlations ($\beta=0.85$ (SE=0.08), which were attenuated in CTCT analyses $r=0.57$ (SE=0.07) and within-pair difference analyses ($\beta=0.74$ (SE=0.10), all $p<0.0001$, Tables 2, 4).

4. Discussion

Our study in cognitively normal older monozygotic twins suggests that in the very early stages of sporadic AD increased levels of A β production markers are associated with A β aggregation as well as higher levels of t-tau and p-tau. CTCT and twin difference analyses indicated that A β production and A β aggregation, A β production and tau markers, and tau and A β aggregation share, at least in part, a common underlying pathology. Furthermore, the moderately strong within twin-pair correlations for aggregation markers and the observation that 14 twin-pairs were discordant for amyloid pathology, suggests that environmental factors influence the start of Alzheimer's disease pathological processes.

In ADAD it has been shown that mutations of the genes amyloid precursor protein (APP), presenilin 1 (PSEN1) or presenilin 2 (PSEN2) cause AD. These mutations can increase A β production, which leads to A β aggregation. To what extent increased A β production, decreased A β clearance, and other factors such as increased neuronal activity, increased inflammation or resistance to γ -secretase activity eventually leads to A β aggregation and neurodegeneration in sporadic AD remains largely unclear. Our findings suggest a role of increased A β production in the very early pathophysiology of sporadic AD. A particularly novel finding in our study is that A β production markers were correlated with t-tau and p-tau levels. Such relationships have previously been reported in studies using induced pluripotent stem cells (iPSC) models where the iPSC-derived purified neurons from sporadic AD showed significantly higher levels of A β 40^{50,51}, and tau¹⁰ compared to controls. The high CTCT and twin difference associations indicates that tau levels and A β production markers may share underlying pathophysiological processes. One such mechanism could be neuronal activity, which dynamically regulates APP cleavage and A β levels^{52,53}. In mouse models, aberrant increased neuronal activity has been observed to precede plaque formation in AD⁵⁴ and such

Preclinical Alzheimer's disease in monozygotic twins

hyperactivity has been related to increased neuronal secretion of both A β and tau, which compromises the metabolic homeostasis of neurons and contribute to network dysfunction^{52,55}. We observed such changes in tau and amyloid towards abnormality very early in the discordant monozygotic twins who had still normal amyloid PET. We further found that A β production markers and tau levels have a shared genetic background. This warrants further investigation into genetic variants causing these changes in large combined genome-wide association studies with CSF.

We found different patterns in the discordant twin-pair analyses between A β production markers BACE1, A β 40 and A β 38. Possibly, this may indicate functional differences between secretases in production of A β peptides, since a previous study using ADAD iPSC-derived neurons showed that mutations of APP and PSEN1 have distinct effects on A β 40 and A β 38 levels by γ -secretase⁵⁶. Future research should further investigate such effects in more detail, by measuring other markers that could reflect γ -secretase activity.

Furthermore, monozygotic twin-pair correlations for A β production markers and t-tau were much higher compared to those of aggregation markers and p-tau. Whether this high correlation resulted from shared genetics or shared environmental factors between twins could not be investigated as we did not include dizygotic twins in our study. However, previous studies indicated that shared environmental factors have a limited effect on neurological and neurodegenerative traits^{4,57}. Future studies are needed to clarify the mechanisms that underlie the differences in amyloid production markers between cognitively normal individuals as this may provide novel clues for reducing A β aggregation and tau phosphorylation.

Monozygotic twin-pair correlations observed for CSF and PET A β aggregation markers and p-tau ranged between 0.49 and 0.52, which similar to previous CSF and PET

Preclinical Alzheimer's disease in monozygotic twins

concordance estimates reported by previous, smaller studies in cognitively normal individuals^{6,7}, and lower compared to twin similarity estimates for AD-type dementia (up to 79%)⁴. It is possible that monozygotic twin similarities in A β aggregation may be lower because of the early disease stage, as the similarity between twins for AD-type dementia increases with age⁴. As such, it is likely that in amyloid discordant pairs, the twin with a normal amyloid-PET visual read may become abnormal in the future, and the notion that such individuals already showed higher BP_{ND} values compared to twin-pairs with both normal amyloid-PET supports this explanation. CTCT and twin difference associations indicated that CSF and PET measures of amyloid aggregation reflect a common underlying pathophysiology. However, associations were moderate, in line with earlier studies⁵⁸, suggesting that they may also capture different aspects of aggregation.

Bigger sample sizes for investigating very early pathophysiology of Alzheimer's disease that include more individuals with abnormal amyloid would be desirable to increase statistical power. However, our older monozygotic twin approach is unique, and has enabled us to estimate the contribution of genetic and environmental factors to the start of A β aggregation. Longitudinal research is needed to investigate whether twin-pairs discordant for amyloid abnormality will become more similar in their levels of A β aggregation and p-tau over time⁴. Furthermore, aberrant CSF A β 1-42/1-40 ratios are evident for AD pathology, but it still remains unclear what differences in CSF A β production markers represent in sporadic AD. In conclusion, previous population studies have indicated that environmental factors influence dementia risk⁵⁹ and our results show that this, at least partially, may be explained through the impact on A β and tau aggregation. Identification of such environmental factors may lead to new ways to prevent AD. In addition, identification of genes and mechanisms associated with

Preclinical Alzheimer's disease in monozygotic twins

high amyloid production in cognitively normal individuals may further provide novel leads to reduce A β aggregation.

Acknowledgments

This work has received support from the EU/EFPIA Innovative Medicines Initiative Joint Undertaking (EMIF grant n° 115372). This work received in kind sponsoring of the CSF assay from ADx NeuroSciences and Euroimmun, and the PET-tracer [^{18}F]flutemetamol from GE Healthcare. We thank all participating twins for their dedication.

Author contributions

EK, JT, MtK, and AdB, collected data. EK, MtK and MMY performed image analysis and SDM and CET CSF analysis. EK, JT, AdB and MGN performed statistical analyses. EK, JT, AdB, BMT and PJV drafted the manuscript. BMT, MtK, MMY, SDM, MGN, HV, AAL, CET, BNMvB, DIB, PHS, and PJV edited the manuscript for critical content. PJV conceived the study, designed the protocol, and provided overall study supervision. All authors read and approved the final version of the manuscript. HV is a co-founder of ADx NeuroSciences and a founder of Biomarkable bvba.

Conflicts of interests

The authors declare the following competing interests:

HV is working on behalf of Biomarkable bvba for ADx NeuroSciences, who provided the ELISA's used in this study.

The other authors do not have a competing interest.

Data availability statement

The data that support the findings of this study are available from the corresponding author after signing a material transfer agreement.

References:

1. Jansen WJ, Ossenkoppele R, Knol DL, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. *JAMA*. 2015;313(19):1924-1938.
2. Sato C, Barthélemy NR, Mawuenyega KG, et al. Tau Kinetics in Neurons and the Human Central Nervous System. *Neuron*. 2018;97(6):1284-1298.e1287.
3. Gordon BA, Blazey TM, Su Y, et al. Spatial patterns of neuroimaging biomarker change in individuals from families with autosomal dominant Alzheimer's disease: a longitudinal study. *Lancet Neurol*. 2018;17(3):241-250.
4. Gatz M, Reynolds CA, Fratiglioni L, et al. Role of genes and environments for explaining Alzheimer disease. *Arch Gen Psychiatry*. 2006;63(2):168-174.
5. Ridge PG, Hoyt KB, Boehme K, et al. Assessment of the genetic variance of late-onset Alzheimer's disease. *Neurobiol Aging*. 2016;41:200 e213-200 e220.
6. Hinrichs AL, Mintun MA, Head D, et al. Cortical binding of pittsburgh compound B, an endophenotype for genetic studies of Alzheimer's disease. *Biol Psychiatry*. 2010;67(6):581-583.
7. Johansson V, Jakobsson J, Fortgang RG, et al. Cerebrospinal fluid microglia and neurodegenerative markers in twins concordant and discordant for psychotic disorders. *Eur Arch Psychiatry Clin Neurosci*. 2016.
8. Mawuenyega KG, Sigurdson W, Ovod V, et al. Decreased Clearance of CNS β -Amyloid in Alzheimer's Disease. *Science*. 2010;330(6012):1774.
9. Selkoe DJ, Hardy J. The amyloid hypothesis of Alzheimer's disease at 25 years. *EMBO Molecular Medicine*. 2016;8(6):595.
10. Knupp A, Mishra S, Martinez R, et al. Depletion of the AD Risk Gene SORL1 Selectively Impairs Neuronal Endosomal Traffic Independent of Amyloidogenic APP Processing. *Cell Rep*. 2020;31(9):107719.
11. Timmers M, Barao S, Van Broeck B, et al. BACE1 Dynamics Upon Inhibition with a BACE Inhibitor and Correlation to Downstream Alzheimer's Disease Markers in Elderly Healthy Participants. *J Alzheimers Dis*. 2017;56(4):1437-1449.
12. Tijms BM, Vermunt L, Zwan MD, et al. Pre-amyloid stage of Alzheimer's disease in cognitively normal individuals. *Annals of Clinical and Translational Neurology*. 2018;5(9):1037-1047.
13. Jack CRJ, Knopman DS, Jagust WJ, et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. In. *Lancet neurology*. Vol 122013:207-216.
14. Barthélemy NR, Li Y, Joseph-Mathurin N, et al. A soluble phosphorylated tau signature links tau, amyloid and the evolution of stages of dominantly inherited Alzheimer's disease. *Nature Medicine*. 2020;26(3):398-407.
15. Small SA, Duff K. Linking Abeta and tau in late-onset Alzheimer's disease: a dual pathway hypothesis. *Neuron*. 2008;60(4):534-542.
16. Zwan MD, Rinne JO, Hasselbalch SG, et al. Use of amyloid-PET to determine cutpoints for CSF markers: A multicenter study. In. *Neurology*. Vol 86: Lippincott Williams & Wilkins; 2016:50-58.

Preclinical Alzheimer's disease in monozygotic twins

17. Boomsma DI, de Geus EJ, Vink JM, et al. Netherlands Twin Register: from twins to twin families. *Twin Res Hum Genet.* 2006;9(6):849-857.
18. Konijnenberg E, Carter SF, ten Kate M, et al. The EMIF-AD PreclinAD study: study design and baseline cohort overview. *Alzheimer's Research & Therapy.* 2018;10(1):75.
19. Morris JC, Heyman A, Mohs RC, et al. The Consortium to Establish a Registry for Alzheimer's Disease (CERAD). Part I. Clinical and neuropsychological assessment of Alzheimer's disease. In. *Neurology.* Vol 39 1989:1159-1165.
20. de Jager CA, Budge MM, Clarke R. Utility of TICS-M for the assessment of cognitive function in older adults. In. *International journal of geriatric psychiatry.* Vol 18 2003:318-324.
21. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. In. *Journal of psychiatric research.* Vol 17 1982:37-49.
22. Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. In. *Neurology.* Vol 43 1993:2412-2414.
23. Lewczuk P, Matzen A, Blennow K, et al. Cerebrospinal Fluid Abeta42/40 Corresponds Better than Abeta42 to Amyloid PET in Alzheimer's Disease. *J Alzheimers Dis.* 2017;55(2):813-822.
24. Portelius E, Westman-Brinkmalm A, Zetterberg H, Blennow K. Determination of β -Amyloid Peptide Signatures in Cerebrospinal Fluid Using Immunoprecipitation-Mass Spectrometry. *Journal of Proteome Research.* 2006;5(4):1010-1016.
25. Tapiola T, Alafuzoff I, Herukka S-K, et al. Cerebrospinal Fluid β -Amyloid 42 and Tau Proteins as Biomarkers of Alzheimer-Type Pathologic Changes in the Brain. *JAMA Neurology.* 2009;66(3):382-389.
26. Buerger K, Ewers M, Pirttilä T, et al. CSF phosphorylated tau protein correlates with neocortical neurofibrillary pathology in Alzheimer's disease. *Brain.* 2006;129(11):3035-3041.
27. Hampel H, Blennow K, Shaw LM, Hoessler YC, Zetterberg H, Trojanowski JQ. Total and phosphorylated tau protein as biological markers of Alzheimer's disease. *Experimental Gerontology.* 2010;45(1):30-40.
28. Mattsson N, Schöll M, Strandberg O, et al. (18)F-AV-1451 and CSF T-tau and P-tau as biomarkers in Alzheimer's disease. *EMBO molecular medicine.* 2017;9(9):1212-1223.
29. La Joie R, Bejanin A, Fagan AM, et al. Associations between [(18)F]AV1451 tau PET and CSF measures of tau pathology in a clinical sample. *Neurology.* 2018;90(4):e282-e290.
30. del Campo M, Mollenhauer B, Bertolotto A, et al. Recommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update. *Biomark Med.* 2012;6(4):419-430.
31. De Vos A, Jacobs D, Struyfs H, et al. C-terminal neurogranin is increased in cerebrospinal fluid but unchanged in plasma in Alzheimer's disease. *Alzheimers Dement.* 2015;11(12):1461-1469.
32. Janelidze S, Pannee J, Mikulskis A, et al. Concordance Between Different Amyloid Immunoassays and Visual Amyloid Positron Emission Tomographic Assessment. *JAMA Neurol.* 2017;74(12):1492-1501.
33. Klunk WE, Engler H, Nordberg A, et al. Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound-B. *Ann Neurol.* 2004;55(3):306-319.
34. Nelissen N, Van Laere K, Thurfjell L, et al. Phase 1 study of the Pittsburgh compound B derivative 18F-flutemetamol in healthy volunteers and patients with probable

- Alzheimer disease. In. *Journal of nuclear medicine : official publication, Society of Nuclear Medicine*. Vol 50: Society of Nuclear Medicine; 2009:1251-1259.
35. Gunn RN, Lammertsma AA, Hume SP, Cunningham VJ. Parametric imaging of ligand-receptor binding in PET using a simplified reference region model. In. *NeuroImage*. Vol 6. 1998/02/07 ed1997:279-287.
36. Wu Y, Carson RE. Noise reduction in the simplified reference tissue model for neuroreceptor functional imaging. In. *Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism*. Vol 22. 2002/12/07 ed2002:1440-1452.
37. Hammers A, Allom R, Koepp MJ, et al. Three-dimensional maximum probability atlas of the human brain, with particular reference to the temporal lobe. *Hum Brain Mapp*. 2003;19(4):224-247.
38. Svarer C, Madsen K, Hasselbalch SG, et al. MR-based automatic delineation of volumes of interest in human brain PET images using probability maps. *Neuroimage*. 2005;24(4):969-979.
39. Tolboom N, Yaqub M, van der Flier WM, et al. Detection of Alzheimer pathology in vivo using both 11C-PIB and 18F-FDDNP PET. *J Nucl Med*. 2009;50(2):191-197.
40. Healthcare G. EPAR product information - summary of product characteristics.
41. Collij L, Konijnenberg E, Reimand J, et al. Assessing Amyloid Pathology in Cognitively Normal Subjects using [(18)F]Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. *J Nucl Med*. 2018.
42. Ehli EA, Abdellaoui A, Fedko IO, et al. A method to customize population-specific arrays for genome-wide association testing. *Eur J Hum Genet*. 2017;25(2):267-270.
43. Fedko IO, Hottenga JJ, Medina-Gomez C, et al. Estimation of Genetic Relationships Between Individuals Across Cohorts and Platforms: Application to Childhood Height. *Behav Genet*. 2015;45(5):514-528.
44. Das S, Forer L, Schonherr S, et al. Next-generation genotype imputation service and methods. *Nat Genet*. 2016;48(10):1284-1287.
45. van der Lee SJ, Wolters FJ, Ikram MK, et al. The effect of APOE and other common genetic variants on the onset of Alzheimer's disease and dementia: a community-based cohort study. *The Lancet Neurology*. 2018;17(5):434-444.
46. Minica CC, Dolan CV, Kampert MM, Boomsma DI, Vink JM. Sandwich corrected standard errors in family-based genome-wide association studies. In. *European journal of human genetics : EJHG*. 2014/06/12 ed2014.
47. Boker S, Neale M, Maes H, et al. OpenMx: An Open Source Extended Structural Equation Modeling Framework. *Psychometrika*. 2011;76(2):306-317.
48. De Moor MH, Boomsma DI, Stubbe JH, Willemsen G, de Geus EJ. Testing causality in the association between regular exercise and symptoms of anxiety and depression. *Arch Gen Psychiatry*. 2008;65(8):897-905.
49. Gatz M, Fratiglioni L, Johansson B, et al. Complete ascertainment of dementia in the Swedish Twin Registry: the HARMONY study. *Neurobiol Aging*. 2005;26(4):439-447.
50. Israel MA, Yuan SH, Bardy C, et al. Probing sporadic and familial Alzheimer's disease using induced pluripotent stem cells. *Nature*. 2012;482(7384):216-220.
51. Meyer K, Feldman HM, Lu T, et al. REST and Neural Gene Network Dysregulation in iPSC Models of Alzheimer's Disease. *Cell Rep*. 2019;26(5):1112-1127.e1119.
52. Bero AW, Yan P, Roh JH, et al. Neuronal activity regulates the regional vulnerability to amyloid-beta deposition. *Nat Neurosci*. 2011;14(6):750-756.
53. Cirrito JR, Yamada KA, Finn MB, et al. Synaptic activity regulates interstitial fluid amyloid-beta levels in vivo. *Neuron*. 2005;48(6):913-922.

Preclinical Alzheimer's disease in monozygotic twins

54. Busche MA, Eichhoff G, Adelsberger H, et al. Clusters of Hyperactive Neurons Near Amyloid Plaques in a Mouse Model of Alzheimer's Disease. *Science*. 2008;321(5896):1686.
55. Zott B, Simon MM, Hong W, et al. A vicious cycle of β amyloid-dependent neuronal hyperactivation. *Science*. 2019;365(6453):559-565.
56. Arber C, Toombs J, Lovejoy C, et al. Familial Alzheimer's disease patient-derived neurons reveal distinct mutation-specific effects on amyloid beta. *Molecular Psychiatry*. 2019.
57. Polderman TJ, Benyamin B, de Leeuw CA, et al. Meta-analysis of the heritability of human traits based on fifty years of twin studies. *Nat Genet*. 2015;47(7):702-709.
58. Zwan M, van Harten A, Ossenkoppele R, et al. Concordance between cerebrospinal fluid biomarkers and [11C]PIB PET in a memory clinic cohort. *Journal of Alzheimer's disease : JAD*. 2014;41(3):801-807.
59. Livingston G, Sommerlad A, Orgeta V, et al. Dementia prevention, intervention, and care. *Lancet*. 2017;390(10113):2673-2734.

Preclinical Alzheimer's disease in monozygotic twins

Table 1. Cohort characteristics

	Total cohort	PET visual read normal	PET visual read abnormal
N [§]	197	167	27
Singletons [^]	7	5	1
Age in years, mean (SD)	70.3 (7.4)	70.0 (7.2)	75.0 (7.2)**
Female gender, n (%)	112 (57)	96 (57)	16 (59)
Years of education, mean (SD)	11.5 (2.6)	11.5 (2.6)	11.4 (3.0)
MMSE, mean (SD)	29.0 (1.1)	29.1 (1.1)	28.6 (1.5)
APOE ε4 carrier [#] , n (%)	65 (33)	50 (30)	14 (52)*
CSF markers, n (%)	126 (64)	105 (63)	18 (67)
- BACE-1, mean (SD), pg/mL	2370 (747)	2306 (696)	2744 (960)
- Amyloid β 1-40, mean (SD), pg/mL	9592 (2844)	9289 (2700)	11409 (3114)
- Amyloid β 1-38, mean (SD), pg/mL	2424 (737)	2370 (715)	2805 (797)
- Ratio amyloid β 1-42/1-40, mean (SD)	0.10 (0.03)	0.10 (0.02)	0.05 (0.02)**
- t-tau, mean (SD), pg/mL	412 (143)	379 (111)	620 (146)
- p-tau, mean (SD), pg/mL	76 (44)	64 (20)	154 (66)**
Dynamic PET, n (%)	188 (95)	162 (97)	26 (96)**
- Global cortical amyloid deposition, mean (SD), BP _{ND}	0.16 (0.12)	0.12 (0.06)	0.43 (0.13)**
- Concordance status visual read amyloid positivity [§] , n (%)			
o Concordant negative pairs	74 (79)		
o Concordant positive pairs	6 (6)		
o Discordant pairs	14 (15)		

[§]PET data missing in 3 subjects. [^]In one pair PET was missing for one subject, the other twin had a normal scan and is counted as singleton for PET analysis. [§]94 twin pairs with both PET visual read available. [#]APOE status missing in 2 subjects. PET visual read was based on BP_{ND} image. MZ = monozygotic; MMSE = mini mental state examination; APOE = apolipoprotein E; CSF = cerebrospinal fluid; Aβ = amyloid beta; BACE = beta secretase; PET = positron emission tomography; BP_{ND} = non-displaceable binding potential; t-tau = total-tau; p-tau = 181-phosphorylated-tau.

*p<0.05 different from normal PET group, for amyloid measures corrected for age, gender, and APOE ε4.

**p<0.01 different from normal PET group, for amyloid measures corrected for age, gender, and APOE ε4.

Preclinical Alzheimer's disease in monozygotic twins

Table 2. Association between amyloid production, amyloid aggregation and tau, among amyloid production, amyloid aggregation and tau in total cohort

Predictor	Dependent	Model 1 β (SE)	p-value	Model 2 β (SE)	p-value
Association amyloid production with amyloid aggregation markers					
CSF BACE-1	CSF ratio Amyloid-β 1-42/1-40	-0.25 (0.10)	0.02	-0.23 (0.09)	0.008
CSF Amyloid-β 1-38	CSF ratio Amyloid-β 1-42/1-40	-0.35 (0.09)	0.0003	-0.27 (0.10)	0.005
CSF BACE-1	PET global [¹⁸ F]flutemetamol binding	0.13 (0.09)	0.12	0.09 (0.09)	0.31
CSF Amyloid-β 1-38	PET global [¹⁸ F]flutemetamol binding	0.17 (0.08)	0.03	0.09 (0.08)	0.23
CSF Amyloid-β 1-40	PET global [¹⁸ F]flutemetamol binding	0.09 (0.09)	0.34	0.02 (0.09)	0.85
Association between amyloid production markers					
CSF BACE-1	CSF Amyloid-β 1-38	0.48 (0.08)	<0.0001	0.45 (0.07)	<0.0001
CSF BACE-1	CSF Amyloid-β 1-40	0.83 (0.07)	<0.0001	0.82 (0.06)	<0.0001
CSF Amyloid-β 1-38	CSF Amyloid-β 1-40	0.80 (0.06)	<0.0001	0.82 (0.07)	<0.0001
Association between amyloid aggregation markers					
Ratio CSF Amyloid-β 1-42/1-40	PET global [¹⁸ F]flutemetamol binding	-0.58 (0.09)	<0.0001	-0.57 (0.09)	<0.0001
Association amyloid aggregation with tau markers					
CSF ratio Amyloid-β 1-42/1-40	CSF t-tau	-0.47 (0.07)	<0.0001	-0.39 (0.08)	<0.0001
PET global [¹⁸ F]flutemetamol binding	CSF t-tau	0.29 (0.07)	<0.0001	0.25 (0.07)	<0.0001
CSF ratio Amyloid-β 1-42/1-40	CSF p-tau	-0.61 (0.09)	<0.0001	-0.54 (0.09)	<0.0001
PET global [¹⁸ F]flutemetamol binding	CSF p-tau	0.50 (0.10)	<0.0001	0.47 (0.10)	<0.0001
Association amyloid production with tau markers					
CSF BACE-1	CSF t-tau	0.63 (0.06)	<0.0001	0.61 (0.05)	<0.0001
CSF Amyloid-β 1-38	CSF t-tau	0.72 (0.08)	<0.0001	0.63 (0.07)	<0.0001
CSF Amyloid-β 1-40	CSF t-tau	0.68 (0.08)	<0.0001	0.63 (0.08)	<0.0001
CSF BACE-1	CSF p-tau	0.60 (0.09)	<0.0001	0.60 (0.07)	<0.0001
CSF Amyloid-β 1-38	CSF p-tau	0.54 (0.10)	<0.0001	0.45 (0.10)	<0.0001
CSF Amyloid-β 1-40	CSF p-tau	0.65 (0.08)	<0.0001	0.61 (0.08)	<0.0001
Association between tau markers					
CSF t-tau	CSF p-tau	0.86 (0.06)	<0.0001	0.85 (0.08)	<0.0001

Generalized estimating equations are shown unadjusted (Model 1) & covariate adjusted for age, APOE ε4 and gender (Model 2). All models include random effect for twin status. Standardized beta's are shown, calculated

Preclinical Alzheimer's disease in monozygotic twins

with z transformed variables. Amyloid aggregation is reflected by higher PET BP_{ND} and lower CSF amyloid- β 1-42/1-40 ratio. CSF = cerebrospinal fluid; Amyloid- β = amyloid beta; BACE = beta secretase; PET = positron emission tomography; t-tau = total-tau; p-tau = 181-phosphorylated-tau.

Table 3. Monozygotic twin-pair correlations

Markers	Correlation (95% CI) Model 1	Correlation (95% CI) Model 2
BACE-1	0.76 (0.76 - 0.80)	0.76 (0.75 - 0.79)
Amyloid- β 1-38	0.88 (0.88 - 0.89)	0.85 (0.85 - 0.87)
Amyloid- β 1-40	0.78 (0.77 - 0.80)	0.76 (0.76 - 0.78)
CSF ratio Amyloid- β 1-42/1-40	0.64 (0.64 - 0.67)	0.50 (0.49 - 0.54)
PET global [¹⁸ F]flutemetamol binding	0.44 (0.44 - 0.50)	0.52 (0.51 - 0.54)
CSF t-tau	0.78 (0.78 - 0.81)	0.70 (0.69 - 0.73)
CSF p-tau	0.61 (0.59 - 0.69)	0.49 (0.47 - 0.56)

Correlation values for association of amyloid markers between one twin and its co-twin (Model 1), corrected for gender, age and APOE status (Model 2); all $p < 0.0001$. Correlations are shown in figure 2. CSF = cerebrospinal fluid; PET = positron emission tomography; BACE = beta secretase; t-tau = total tau; p-tau = 181-phosphorylated-tau.

Table 4. Cross-twin cross trait and within twin-pair difference analyses

		A. Cross-twin cross-trait				B. Within twin-pair difference			
		Model 1		Model 2		Model 1		Model 2	
		R (SE); 95%CI	p-value	R (SE); 95%CI	p-value	β (SE)	p-value	β (SE)	p-value
Association between amyloid aggregation markers									
Ratio CSF Amyloid-β 1-42/1-40	PET global [18F]flutemetamol binding	-0.42 (0.08); (-0.56 – -0.26)	<0.0001	-0.33 (0.09); (-0.49 – -0.15)	0.0005	-0.56 (0.13)	<0.0001	-0.58 (0.14)	<0.0001
Associations between amyloid production and aggregation markers									
BACE-1	Ratio CSF Amyloid-β 1-42/1-40	-0.19 (0.10); (-0.38 – 0.01)	0.06	-0.18 (0.10); (-0.37 – 0.01)	0.07	-0.16 (0.14)	0.26	-0.13 (0.14)	0.34
Amyloid-β 1-38	Ratio CSF Amyloid-β 1-42/1-40	-0.36 (0.09); (-0.53 – -0.16)	0.0005	-0.24 (0.10); (-0.46 – -0.08)	0.007	-0.07 (0.14)	0.61	-0.05 (0.14)	0.72
Amyloid-β 1-38	PET global [18F]flutemetamol binding	0.23 (0.09); (0.02 – 0.41)	0.03	0.16 (0.10); (-0.08 – 0.33)	0.22	0.08 (0.16)	0.63	0.08 (0.16)	0.64
Associations between amyloid aggregation and tau markers									
CSF ratio Amyloid-β 1-42/1-40	CSF t-tau	-0.53 (0.07); (-0.66 – -0.37)	<0.0001	-0.39 (0.09); (-0.55 – -0.21)	<0.0001	-0.40 (0.13)	0.003	-0.36 (0.13)	0.009
PET global [18F]flutemetamol binding	CSF t-tau	0.37 (0.09); (0.19 – 0.53)	0.0001	0.25 (0.10); (0.05 – 0.42)	0.015	0.41 (0.13)	0.002	0.40 (0.13)	0.003
CSF ratio Amyloid-β 1-42/1-40	CSF p-tau	-0.54 (0.07); (-0.67 – -0.37)	<0.0001	-0.39 (0.09); (-0.55 – -0.20)	0.0001	-0.53 (0.12)	<0.0001	-0.53 (0.12)	<0.0001
PET global [18F]flutemetamol binding	CSF p-tau	0.36 (0.08); (0.18 – 0.51)	0.0001	0.22 (0.10); (0.03 – 0.40)	0.025	0.69 (0.10)	<0.0001	0.67 (0.10)	<0.0001
Associations between amyloid production and tau markers									
BACE-1	CSF t-tau	0.51 (0.08); (0.35 – 0.65)	<0.0001	0.56 (0.07); (0.41 – 0.69)	<0.0001	0.63 (0.11)	<0.0001	0.61 (0.11)	<0.0001
Amyloid-β 1-38	CSF t-tau	0.65 (0.06); (0.51 – 0.75)	<0.0001	0.58 (0.07); (0.43 – 0.70)	<0.0001	0.53 (0.12)	<0.0001	0.52 (0.12)	<0.0001

Amyloid- β 1-40	CSF t-tau	0.62 (0.07); (0.47 – 0.73)	<0.0001	0.58 (0.07); (0.42 – 0.70)	<0.0001	0.59 (0.11)	<0.0001	0.58 (0.11)	<0.0001
BACE-1	CSF p-tau	0.48 (0.08); (0.31 – 0.63)	<0.0001	0.54 (0.07); (0.37 – 0.67)	<0.0001	0.50 (0.12)	<0.0001	0.49 (0.12)	<0.0001
Amyloid- β 1-38	CSF p-tau	0.42 (0.09); (0.23 – 0.58)	<0.0001	0.32 (0.10); (0.12 – 0.50)	0.002	0.48 (0.12)	<0.0001	0.49 (0.12)	<0.0001
Amyloid- β 1-40	CSF p-tau	0.53 (0.08); (0.37 – 0.67)	<0.0001	0.51 (0.08); (0.35 – 0.65)	<0.0001	0.54 (0.12)	<0.0001	0.54 (0.12)	<0.0001
Associations between amyloid production markers									
BACE-1	Amyloid- β 1-38	0.45 (0.09); (0.26 – 0.60)	<0.0001	0.41 (0.09); (0.24 – 0.58)	<0.0001	0.57 (0.11)	<0.0001	0.57 (0.12)	<0.0001
BACE-1	Amyloid- β 1-40	0.67 (0.06); (0.54 – 0.77)	<0.0001	0.66 (0.06); (0.53 – 0.77)	<0.0001	0.73 (0.09)	<0.0001	0.73 (0.10)	<0.0001
Amyloid- β 1-38	Amyloid- β 1-40	0.62 (0.07); (0.48 – 0.73)	<0.0001	0.51 (0.08); (0.41 – 0.69)	<0.0001	0.78 (0.09)	<0.0001	0.78 (0.09)	<0.0001
Associations between tau markers									
CSF t-tau	CSF p-tau	0.68 (0.06); (0.55 – 0.78)	<0.0001	0.57 (0.07); (0.41 – 0.70)	<0.0001	0.74 (0.09)	<0.0001	0.74 (0.10)	<0.0001

A. Cross-twin cross-trait. Data are displayed as correlation coefficient (SE), comparable to standardized beta's given in GEE results. Unadjusted (Model 1), calculated for residuals adjusted for age, APOE ϵ 4 and gender (Model 2). Correlation coefficient indicates the correlation of the production marker in one twin with the aggregation marker in its co-twin. Cross-twin cross-trait analyses are shown for variables that had a statistically significant association in the whole cohort (Table 2).

B. Within twin-pair difference. Linear regression results are shown for the relation between the standardized difference scores (z-scores) within a twin-pair per amyloid marker (Model 1), and adjusted for age, APOE ϵ 4 and gender (Model 2). Beta indicates the association between the within-pair difference in the production marker and the within-pair difference in the aggregation marker. Within-pair difference analyses are shown for variables that had a statistically significant association in the whole cohort (Table 2).

CTCT = cross-twin cross-trait; CSF = cerebrospinal fluid; Amyloid- β = amyloid beta; BACE = beta secretase; PET = positron emission tomography; t-tau = total-tau; p-tau = 181-phosphorylated-tau

Preclinical Alzheimer's disease in monozygotic twins

Fig. 1. Patterns of amyloid production, amyloid aggregation and tau for twin discordance

Fig. 2. Monozygotic twin-pair correlations

Fig. 3. Monozygotic within-pair difference associations between amyloid aggregation markers, amyloid production markers and tau

FIGURE LEGENDS

Fig. 1. Patterns of amyloid production, amyloid aggregation and tau for twin discordance

[18F]flutemetamol PET images from a concordant twin pair (A) with a normal scan, a discordant pair (B) and a concordant pair with an abnormal scan (C). Boxplots show BACE1 (D); amyloid- β 1-40 (E); amyloid- β 1-38 (F); amyloid- β 1-42/1-40 ratio (G); global cortical PET binding (H); t-tau (I); and p-tau (J) for twins who have both a normal amyloid-PET scan (concordant normal, n=148 of which 93 have CSF markers), twins from a discordant pair with a normal amyloid-PET (discordant normal, n=14 of which 8 have CSF markers), twins from a discordant pair with abnormal amyloid-PET (discordant abnormal, n=14 of which 9 have CSF markers), and twin pairs who both have an abnormal amyloid-PET scan (concordant abnormal, n=12, of which 9 have CSF markers). All analyses for group comparisons were corrected for age, APOE ϵ 4 and gender. *p<0.05; **p<0.01. CSF = cerebrospinal fluid; PET = positron emission tomography; BACE = beta secretase; t-tau = total-tau; p-tau = 181-phosphorylated-tau.

Fig. 2. Monozygotic twin-pair correlations

Partial correlation values for association of amyloid markers between one twin and its co-twin, corrected for gender, age and APOE ϵ 4 (Model 2); all p<0.0001. Each dot represents one twin pair. From left to right: CSF BACE1; CSF amyloid- β 1-40; CSF amyloid- β 1-38; CSF amyloid- β 1-42/1-40 ratio; global cortical PET binding (BP_{ND}); CSF t-tau; CSF p-tau. CSF = cerebrospinal fluid; PET = positron emission tomography; BACE = beta secretase; t-tau = total-tau; p-tau = 181-phosphorylated-tau.

Fig. 3. Monozygotic within-pair difference associations between amyloid aggregation markers, amyloid production markers and tau

Preclinical Alzheimer's disease in monozygotic twins

Within-pair differences of (A) CSF amyloid- β 1-42/1-40 ratio with global cortical PET binding (BP_{ND}); (B) CSF BACE1 with CSF amyloid- β 1-38; (C) CSF BACE1 with CSF amyloid- β 1-40; (D) CSF amyloid- β 1-38 with CSF amyloid- β 1-40; (E) CSF t-tau with CSF p-tau; (F) CSF amyloid- β 1-42/1-40 ratio with CSF t-tau; (G) global cortical PET binding (BP_{ND}) with CSF t-tau; (H) CSF amyloid- β 1-42/1-40 ratio with CSF p-tau; (I) global cortical PET binding (BP_{ND}) with CSF p-tau; (J) CSF BACE1 with CSF t-tau; (K) CSF amyloid- β 1-38 with CSF t-tau; (L) CSF amyloid- β 1-40 with CSF t-tau; (M) CSF BACE1 with CSF p-tau; (N) CSF amyloid- β 1-38 with CSF p-tau; (O) CSF amyloid- β 1-40 with CSF p-tau. Each dot represents one twin pair, twin pairs who are concordant normal on visual amyloid-PET read are shown as open triangles, twin pairs who are concordant abnormal on visual amyloid-PET read are shown as squares with a cross inside. Discordant pairs on visual amyloid-PET read are shown as black dots. Lower CSF ratio amyloid beta 1-42/1-40 and higher global cortical PET binding indicate more amyloid aggregation. CSF = cerebrospinal fluid; PET = positron emission tomography; BACE = beta secretase; t-tau = total-tau; p-tau = 181-phosphorylated-tau.